In October 2016, Galychpharm, a part of Arterium Corporation, passed assessment by the Belarusian GMP inspectorate. The Centre for Examination and Tests in Health Service with the Ministry of Health of the Republic of Belarus confirmed the company’s drug production complied with the license conditions and GMP-certified areas of the facility fully satisfied the requirements of the Good Manufacturing Practices of the Republic of Belarus.
The inspection encompassed two production areas and manufacturing practices for such renown medicinal products as Urolesan, Sedavit, Inspiron, Thiotriazolin, L-lysine Aescinat and Thiocetam made there. “Belarusian regulating authorities have confirmed that Galychpharm’s drug production complies with the highest standards of the pharmaceutical industry. Our medicinal products, which enjoy robust demand in Belarus, will thus remain accessible to local medics and patients alike,” Serhii Sur, Regulatory Affairs Director at Arterium Corporation said.
This was the second inspection of Arterium’s facilities by Belarusian regulators. In June 2015, specialists of the Centre for Examination and Tests in Health Service verified compliance of Kievmedpreparat’s solids production shop with the Belarusian GMP guidelines.
Arterium Corporation has been present in Belarus since 2006. The company offers 39 drugs in this market and is among the top 30 companies by sales value here.